Using genetic variants to evaluate the causal effect of cholesterol

lowering on head and neck cancer risk: a Mendelian randomization

study

Mark Gormley[1,2,3]*, James Yarmolinsky[1,3], Tom Dudding[1,2,3], Kimberley Burrows[1,3], Richard M

Martin[1,3,4], Steven Thomas[2,4], Jessica Tyrrell[5], Paul Brennan[6], Miranda Pring[2], Stefania

Boccia[7,8], Andrew F Olshan[9], Brenda Diergaarde[10], Rayjean J. Hung[11,12], Geoffrey Liu[12,13],

Danny Legge[14], Eloiza H Tajara[15], Patricia Severino [16], Martin Lacko[17], Andrew R Ness[4],

George Davey Smith[1,3], Emma E Vincent[1,3,14&], Rebecca C Richmond[1,3&]

[1] MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School,

University of Bristol, Bristol, UK.

[2] Bristol Dental Hospital and School, University of Bristol, Bristol, UK.

[3] Department of Population Health Sciences, Bristol Medical School, University of Bristol,

Bristol, UK.

[4] National Institute for Health Research Bristol Biomedical Research Centre at the University

Hospitals Bristol and Weston NHS Foundation Trust, University of Bristol, Bristol, UK.

[5] University of Exeter Medical School, RILD Building, RD&E Hospital, Exeter, UK.

[6] Genetic Epidemiology Group, World Health Organization, International Agency for

Research on Cancer, Lyon, France.

[7] Sezione di Igiene, Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma,

Italy.

[8] Department of Woman and Child Health and Public Health, Public Health Area, Fondazione

Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.

[9] Department of Epidemiology, Gillings School of Global Public Health, University of North

Carolina, US.

[10] Department of Human Genetics, Graduate School of Public Health, University of

Pittsburgh, and UPMC Hillman Cancer Center, Pittsburgh, US.

[11] Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research

Institute, Sinai Health System, Toronto, Canada.

[12] Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.

[13] Princess Margaret Cancer Centre, Toronto Canada.

[14] School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

[15] School of Medicine of São José do Rio Preto, São Paulo, Brazil.

[16] Albert Einstein Research and Education Institute, Hospital Israelita Albert Einstein, São

Paulo, Brazil.

[17] Department of Otorhinolaryngology and Head and Neck Surgery, Research Institute

GROW, Maastricht University Medical Center, Maastricht, The Netherlands.

Corresponding author

* Email: mark.gormley@bristol.ac.uk

Author contributions

& These authors also contributed equally to this work.

E.E.V. and R.C.R. are joint senior authors. M.G., R.C.R. and E.E.V. conceived the study and M.G. carried out data curation and formal analysis. K.B. performed the GWAS of head and neck cancer in UK Biobank. Head and neck cancer summary genetic data was obtained through multiple collaborations from studies lead and curated by A.R.N., S.T., A.F.O., B.D., R.J.H., G.L., M.L., E.T., S.B. and P.B. Expert guidance on MR methodology was provided by R.C.R., J.Y., G.D.S. and R.M.M., R.C.R., G.D.S, J.T., S.T., P.B., R.M.M. and A.R.N. provided expertise on both observational and genetic epidemiological methodology and analysis. The initial manuscript was drafted by M.G., R.C.R. and E.E.V. All authors (M.G., J.Y., T.D., K.B., R.M.M., S.T., J.T., A.R.N., P.B., M.P., S.B., A.F.O., B.D, R.J.H., G.L., D.L., E.H.T., P.S., M.L., A.R.N., G.D.S., E.E.V. and R.C.R.) contributed to the interpretation of the results, editing and critical revision of the manuscript. M.G.'s PhD supervisory team includes R.C.R., E.E.V., J.T., A.R.N and G.D.S.

Abbreviations: HNSCC, head and neck squamous cell carcinoma; OC, oral cancer; OPC,

oropharyngeal cancer; HPV, human papilloma virus; MR, Mendelian randomization; GWAS,

genome-wide association study; SNP, single nucleotide polymorphism; PCA, principal

component analysis; NOME, no measurement error; SIMEX, simulation extrapolation; MR-

PRESSO, Mendelian Randomization Pleiotropy RESidual Sum and Outlier; GAME-ON, Genetic

Associations and Mechanisms in Oncology; HMGCR, 3-hydroxy-3-methylglutaryl-CoA

reductase; NPC1L1, NPC1 like intracellular cholesterol transporter 1; CETP, cholesteryl ester

transfer protein; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, low-density

lipoprotein receptor; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density

lipoprotein cholesterol; LD, linkage disequilibrium; OR, odds ratio; se, standard error; IVW,

inverse variance weighted; CI, confidence intervals; P, *p*-value.

Abstract

Introduction

Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral

cavity and oropharynx, is a cause of substantial global morbidity and mortality. Strategies to

reduce disease burden include discovery of novel therapies and repurposing of existing

drugs. Statins are commonly prescribed for lowering circulating cholesterol by inhibiting

HMG-CoA reductase (HMGCR). Results from some observational studies suggest that statin

use may reduce HNSCC risk.   We appraised the relationship of genetically-proxied

cholesterol-lowering drug targets and other circulating lipid traits with oral (OC) and

oropharyngeal (OPC) cancer risk.

Methods and findings

We conducted two-sample Mendelian randomization (MR). For the primary analysis,

germline genetic variants in *HMGCR*, *NPC1L1*, *CETP, PCSK9* and *LDLR* were used to proxy the

effect of low-density lipoprotein cholesterol (LDL-C) lowering therapies. In secondary

analyses, variants were used to proxy circulating levels of other lipid traits in a genome-wide

association study (GWAS) meta-analysis of 188,578 individuals. Both primary and secondary

analyses aimed to estimate the downstream causal effect of cholesterol lowering therapies

on OC and OPC risk.

The second sample for MR was taken from a GWAS of 6,034 OC and OPC cases and

6,585 controls (GAME-ON). Analyses were replicated in UK Biobank, using 839 OC and OPC

cases and 372,016 controls and the results of the GAME-ON and UK Biobank analyses

combined in a fixed-effects meta-analysis.

We found limited evidence of a causal effect of genetically-proxied LDL-C lowering

using HMGCR, NPC1L1, CETP or other circulating lipid traits on either OC or OPC risk.

Genetically-proxied PCSK9 inhibition equivalent to a 1 mmol/L (38.7 mg/dL) reduction in

LDL-C was associated with an increased risk of OC and OPC combined (OR 1.8 95%CI 1.2, 2.8,

p= 9.31 x10^{-05}), with good concordance between GAME-ON and UK Biobank (I^2= 22%).

Effects for PCSK9 appeared stronger in relation to OPC (OR 2.6 95%CI 1.4, 4.9) than OC (OR

1.4 95%CI 0.8, 2.4). LDLR variants, resulting in genetically-proxied reduction in LDL-C

equivalent to a 1 mmol/L (38.7 mg/dL), reduced the risk of OC and OPC combined (OR 0.7,

95%CI 0.5, 1.0, p= 0.006). A series of pleiotropy-robust and outlier detection methods

showed that pleiotropy did not bias our findings.

Conclusion

We found limited evidence for a role of cholesterol-lowering in OC and OPC risk,

suggesting previous observational results may have been confounded. There was some

evidence that genetically-proxied inhibition of PCSK9 increased risk, while lipid-lowering

variants in LDLR, reduced risk of combined OC and OPC. This result suggests that the

mechanisms of action of PCSK9 on OC and OPC risk may be independent of its cholesterol

lowering effects, but further replication of this finding is required.

Author summary

Why was this study done?

- To determine if genetically-proxied cholesterol-lowering drugs (such as statins which target HMGCR) reduce oral and oropharyngeal cancer risk.

- To determine if genetically-proxied circulating lipid traits (e.g. low-density lipoprotein cholesterol) have a causal effect on oral and oropharyngeal cancer risk.

What did the researchers do and find?

- There was little evidence that genetically-proxied inhibition of HMGCR (target of statins), NPC1L1 (target of ezetimibe) and CETP (target of CETP inhibitors) influences oral or oropharyngeal cancer risk.

- There was little evidence of an effect of circulating lipid traits on oral or oropharyngeal cancer risk.

- There was some evidence that genetically-proxied inhibition of PCSK9 increases, while lipid-lowering variants in LDLR reduces oral and oropharyngeal cancer risk .

What do these findings mean?

- These findings suggest that the results of previous observational studies examining the effect of statins on oral and oropharyngeal risk may have been confounded.

- Given we found little evidence of an effect of other cholesterol lowering therapies, the mechanism of action of PCSK9 may be independent of cholesterol-lowering. Further replication of this finding in other head and neck cancer datasets is required.

Introduction

Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral

cavity (OC) and oropharynx (OPC), is the sixth most common cancer in the world, with over

550,000 new cases and 300,000 deaths annually [1, 2]. Despite some modest improvements

in the treatment of HNSCC, survival ranges between 19 - 59% at 10 years [3] and recurrence

rates remain high [4]. Patients often undergo a combination of surgery, radiotherapy and

chemotherapy which can result in significant morbidity [5]. Established risk factors include

smoking, alcohol and human papilloma virus (HPV), the latter mainly linked with

oropharyngeal cancer [6, 7]. Given that in contemporary cohorts, around 70% of OPC cases

(versus <5% of OC cases) are HPV driven and often present in younger populations, oral and

oropharyngeal tumours are considered distinct disease entities, with different risk factor

profiles [8]. Despite smoking cessation, alcohol reduction measures and the implementation

of HPV vaccination in some areas, HNSCC remains a major global health problem [2]. Novel

strategies for prevention of HNSCC are required, in particular for those at high risk and one

approach is to identify novel risk factors which can be easily modified, for example by

repurposing existing drugs [9].

Statins are one of the most commonly prescribed medications worldwide. They are

prescribed to reduce levels of circulating total and low-density lipoprotein cholesterol (LDL-

C), with proven preventative and therapeutic effects in cardiovascular disease and a good

safety profile [10, 11]. Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase

(HMG-CoA reductase (HMGCR)), the rate-limiting enzyme in the mevalonate pathway,

responsible for cholesterol and steroid hormone synthesis [12]. Other clinically approved

drugs that target cholesterol metabolism via different mechanisms include ezetimibe

(targeting Niemann-Pick C1-like protein (NPC1L1)) and proprotein convertase

subtilisin/kexin type 9 (PCSK9) inhibitors such as evolocumab or alirocumab. These agents

act by reducing the intestinal absorption of cholesterol or by enhancing uptake of LDL-C

through increased cellular membrane expression of the LDL-receptor (LDLR), respectively.

Conversely, cholesteryl ester transfer protein inhibitors (CETP) substantially increase levels

of high-density lipoprotein cholesterol (HDL-C), lower levels of LDL-C and enhance reverse

cholesterol transport [13].

Cholesterol is vital for a variety of key cellular functions, including membrane

integrity, signalling, protein synthesis and cell cycle progression. Therefore, modulation of

cholesterol synthesis has the potential to influence several hallmarks of tumourigenesis

including cell migration and proliferation [14]. In an experimental study, mice given oral

daily doses of simvastatin two weeks prior to subcutaneous injection of FaDu (HPV-negative

hypopharyngeal tumour cells), showed a significant reduction in tumour growth. This study

was designed to mimic a clinical scenario where patients who present with a tumour may

have been taking the medication prior to tumour initiation [15], and suggested that

simvastatin antagonises tumour metabolic reprogramming, another important hallmark of

cancer [15]. Mechanistic support for the role of LDL-C lowering in cancer development

comes largely from the fact that lipids are themselves major cell membrane components

essential for cell division and maintaining tissue integrity. Changes in lipid levels have been

reported associated with tumour development [16, 17].

However, the evidence that cholesterol-lowering drugs may reduce the risk of head

and neck cancer is limited. Some observational studies report an inverse association of

taking statins with both head and neck cancer risk and survival [14, 18], but others indicate

little evidence of any effect [19]. Observational studies are not randomised and are

susceptible to reverse causality and/or confounding [19]. Mendelian randomization (MR) is

an approach that uses germline genetic proxies (referred to as instruments) to help appraise

causal effects of potentially modifiable extrinsic exposures or intrinsic traits with disease

[20-22]. It has also been used to estimate therapeutic potential by investigating genetic

variation at drug targets [23]. Numerous single nucleotide polymorphisms (SNPs) are

associated with lower levels of circulating LDL-C [24, 25] and inheriting an LDL-C lowering

allele has been proposed to be analogous to being assigned life-long treatment with a

cholesterol lowering drug [26]. In this way, germline genetic variants may serve as proxies

for exposure to potential pharmacological agents which are less likely than observational

measures to be subject to reverse causation or confounding. Genetic proxies can therefore

be used to predict both the likely beneficial and adverse effects of long-term modulation of

the drug targets on disease.

MR has previously demonstrated the protective effect of cholesterol-lowering drugs

on cardiovascular disease risk [27] , but also that inhibition of HMGCR and PCSK9 may have

an adverse effect on diabetes risk [28]. Of relevance to cancer, some recent MR studies have

shown that genetically-proxied inhibition of HMGCR may be protective against overall

cancer [29] and epithelial ovarian cancer [30] risk. Our aim was to use MR to appraise the

causal nature and mechanistic basis of the relationship between cholesterol-lowering and

risk of oral and oropharyngeal cancer by investigating germline variation in HMGCR,

NPC1L1, CETP, PCSK9 and LDLR, and other related lipid traits such as circulating LDL-C.

Methods

Identifying cholesterol-lowering genetic instruments. For the primary analysis, SNPs in

HMGCR, *NPC1L1*, *CETP, PCSK9* and *LDLR* were used to proxy the effect of lipid-lowering

therapies and to estimate the downstream effect of manipulating these targets on OC and

OPC risk. SNPs were identified within 100 kb on either side of the target gene (*HMGCR*,

NPC1L1, CETP, PCSK9 and *LDLR)* that were associated with LDL-C levels. Variants were

robustly associated with LDL-C in a meta-analysis of genome-wide association studies

(GWAS) involving 188,578 individuals primarily (96%) of European ancestry in the Global

Lipids Genetic Consortium (GLGC) [25]. Linkage disequilibrium (LD) (r^2) was evaluated to

check the overlap between variants using LDmatrix (4.0 Release) [31]. Proxy SNPs were

permitted to be in weak LD ($r^2 <0.2$) with each other, to increase the proportion of variance

explained in each respective drug target therefore maximising instrument strength. Multiple

papers have used these genetic instruments at this threshold, to demonstrate causal effects

in cardiovascular disease [13, 27, 32], diabetes [28] and ovarian cancer [30]. In secondary

analyses, SNPs were used to proxy circulating levels of LDL-C, HDL-C, total triglyceride, total

cholesterol, apolipoprotein A and B. Betas represented the change in lipid trait levels per

copy of the effect allele. These SNPs were already independently ($r^2 <0.001$) associated with

the respective traits in large GWAS which have been described previously [25, 33].

Summary level genetic data on oral and oropharyngeal cancer from GAME-ON.

We estimated the effects of the cholesterol-lowering genetic variants on risk of OC and OPC

using GWAS performed on 6,034 cases and 6,585 controls from 12 studies which were part

of the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network [34]. The

study population included participants from Europe (45.3%), North America (43.9%) and

South America (10.8%). Cancer cases comprised the following the International

Classification of Diseases (ICD) codes: oral cavity (C02.0-C02.9, C03.0-C03.9, C04.0-C04.9,

C05.0-C06.9) oropharynx (C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9),

overlapping (C14 and combination of other sites) and 25 cases with unknown ICD code

(other). A total of 954 individuals with cancers of hypopharynx, unknown code or

overlapping cancers were excluded. Genomic DNA isolated from blood or buccal cells was

genotyped at the Center for Inherited Disease Research (CIDR) using an Illumina OncoArray

custom designed for cancer studies by the OncoArray Consortium [35]. In GAME-ON, all

SNPs with a call rate of <95% were excluded. Given the ethnic heterogeneity of the study

population, the dataset was divided by geographical region and SNPs within each region

that showed deviation from Hardy-Weinberg Equilibrium (HWE) in controls (p= <1 x10^{-7})

were excluded. Principal component analysis (PCA) was performed using approximately

10,000 common markers in low LD (r^2 <0.004), minor allele frequency (MAF) >0.05 and 139

population outliers were removed. Full details of the included studies, as well as the

genotyping and imputation performed, have been described previously [34, 36].

Two-sample Mendelian randomization. Two-sample MR was conducted using the

"TwoSampleMR" package in R (version 3.5.3), by integrating SNP associations for

cholesterol-lowering (sample 1) with those for OC and OPC in GAME-ON (sample 2). For

those SNPs instrumenting LDL-C lowering, we first extracted summary statistics for the

associations with OC and OPC from GAME-ON. We next performed harmonisation of the

direction of effects between the cholesterol-lowering exposures and outcome (OC or OPC)

where, for each variant, the allele designated the 'exposure allele' was associated with

lower LDL-C levels and palindromic SNPs were aligned when MAFs were <0.3 or were

otherwise excluded. In our primary analysis, four palindromic SNPs, one in *HMGCR*

(rs2006760), the other in *PCSK9* (rs2149041) and two in *CETP* (rs5880, rs9929488) were

removed. In the secondary analysis with other lipid traits, 11 palindromic SNPs (rs1936800,

rs2288912, rs7112577, rs964184, rs150617279, rs1883711, rs4722043, rs2156552,

rs2954029, rs581080, rs7534572) were removed.

Individual effect-estimates for each SNP were calculated using the Wald ratio, by

dividing the SNP-outcome association by the SNP-exposure association. Multiple SNPs were

then combined into multi-allelic instruments using the random-effects inverse-variance

weighted (IVW) meta-analysis method, for each of the genes *HMGCR, NPC1L1, CETP, PCSK9*

and *LDLR*. This meta-analysis was undertaken to increase the proportion of variance in drug

targets and LDL-C lowering explained by each instrument, and thus improve statistical

power and the precision of our estimates [37]. The analysis produced an estimate of the

effect of the risk factor on OC and OPC risk. As the instruments for *HMGCR, NPC1L1, CETP,*

PCSK9 and *LDLR* were in weak LD (r^2 <0.2), we accounted for this correlation between SNPs

in the primary analysis using LDlink (4.0 Release) which employs Phase 3 (Version 5) of the

1000 Genomes Project and variant rs numbers based on dbSNP. Correlation matrices were

inserted as an MRInput object [31], resulting in MR methods which altered the weightings

for correlated SNPs. For circulating lipid traits, a more stringent r^2 <0.001 was already

applied in the initial GWAS [25], so we did not account further for correlation in the

secondary analysis. We computed odds ratios (OR) which represent the change in odds of

oral and oropharyngeal squamous cell carcinoma per genetically-proxied inhibition of the

drug target, equivalent to a 1 mg/dl decrease in LDL-C. The OR was scaled to be per 1

mmol/L decrease by dividing the LDL-C lowering effect (beta) and standard error (se)

measured in mg/dL by 38.7 [30]. The betas and standard errors for *HMGCR*, *NPC1L1*, *CETP*,

PCSK9 and *LDLR* SNPs were also converted to reflect the cholesterol-lowering effect, given

the "TwoSampleMR" package preference to automatically change these into a positive

direction of effect (i.e. lipid increasing). The correct direction of effect was checked using a

positive control of coronary heart disease from the CARDIoGRAM GWAS data [38]. MR was

also used to examine the effect of circulating levels of LDL-C, HDL-C, total triglyceride, total

cholesterol, apolipoprotein A and B levels directly with OC and OPC cancer risk. The ORs in

this analysis represent the change in odds of oral or oropharyngeal squamous cell

carcinoma, per SD unit increase in lipid trait.

The IVW method can provide an unbiased effect estimate in the absence of

horizontal pleiotropy or when horizontal pleiotropy is balanced [39]. We therefore

performed sensitivity analyses to evaluate the potential for unbalanced horizontal

pleiotropy, where genetic variants influence two or more traits through independent

biological pathways. To ensure the genetic instrument was associated with the instrument it

was proxying, estimates of the proportion of variance in each risk factor explained by the

instrument (R^2) and F-statistics were generated. An F-statistic of <10 is indicative of a weak

instrument which may be subject to weak instrument bias. To account for directional

pleiotropy, we compared the IVW results with three MR sensitivity analyses, which each

make different assumptions: MR Egger [40], weighted median [41] and weighted mode [42].

While these three methods are best used when genetic instruments consist of a large

numbers of independent SNPs, since r^2 values between SNPs in our instruments were low

(r^2 <0.2), we a-priori decided to include them, with a further sensitivity analysis to account

for correlation in the MR Egger analysis. The weighted median stipulates that at least 50% of

the weight in the analysis stems from variants that are valid instruments [41], while the

weighted mode requires that the largest subset of instruments which identify the same

causal effect to be valid instruments [42]. MR-Egger can provide unbiased estimates even

when all SNPs in an instrument violate the exclusion restriction assumption (i.e. affect the

outcome by means other than via the risk factor of interest). However, there must be

negligible measurement error (NOME) [43] in the genetic instrument and the InSIDE

(Instrument Strength Independent of Direct Effect) assumption must be satisfied [40].

Where there was evidence of violation of the NOME assumption, this was assessed using

the I^2 statistic and MR-Egger was performed with simulation extrapolation (SIMEX)

correction [43]. To further assess the robustness of findings, we examined evidence of

heterogeneity in the individual SNP estimates using the Cochran Q-statistic, which may

indicate the presence of invalid instruments (e.g. due to horizontal pleiotropy) [44]. Scatter

and leave-one-out plots were produced to evaluate influential outliers and MR-PRESSO

(Mendelian Randomization Pleiotropy RESidual Sum and Outlier) was used to detect and

correct for potential outliers (where Q-statistic $p < 0.05$) [45].

Stratification by cancer subsite. Given the difference in established aetiology (i.e. smoking, alcohol and HPV) at each HNSCC subsite [6], we performed MR analyses with stratification by cancer subsite to evaluate potential heterogeneity in effects. For this, we used GWAS summary data on a subset of 2,641 OPC cases and 2,990 OC cases from the 6,034 HNSCC cases and the 6,585 common controls in the GAME-ON GWAS [34].

Replication in UK Biobank. UK Biobank data was used as a replication dataset for primary analyses. A GWAS was performed on 839 combined OC and OPC cases and 372,016 controls, with two further stratified GWAS for OC (n= 357) and OPC (n= 494). UK Biobank is a large population-based cohort study that recruited over 500,000 men and women aged between 37 and 73 years between 2006 and 2010 throughout the UK. It received ethical approval from the National Health Service North West Centre for Research Ethics Committee (reference: 11/NW/0382). Details of genotyping quality control, phasing and imputation are described elsewhere [46]. Participant records are linked to cancer registry data and HNSCC was grouped using the same ICD-codes as described above. Squamous cell carcinoma cases were identified using histology codes 8070 – 8078. All GWAS analyses were adjusted for the top 10 genetic principal components, age, and sex. Primary MR analyses as described above in GAME-ON were repeated in UK Biobank data.

Meta-analysis of results. We performed both fixed-effects and random-effects meta-analysis of the MR estimates in GAME-ON and UK Biobank using the R package 'meta'. However, we focus more on the fixed-effects estimates since we assume that the causal effect is constant between the studies [47]. Heterogeneity between study populations was assessed using I^2 statistic [48].

Results

Primary analysis in GAME-ON. In total, 5 SNPs in *HMGCR* (rs12916, rs17238484, rs5909,

rs2303152, rs10066707) were used to proxy HMG-CoA reductase inhibition (statins); 5 SNPs

in *NPC1L1* (rs217386, rs2073547, rs7791240, rs10234070, rs2300414) proxied NPC1L1

inhibition (ezetimibe); 6 SNPs in *CETP* (rs9989419, rs12708967, rs3764261, rs1800775,

rs1864163, rs289714) proxied CETP inhibition; 6 SNPs in *PCSK9* (rs11206510, rs2479409,

rs2479394, rs10888897, rs7552841, rs562556) proxied PCSK9 inhibition; 3 SNPs proxied

cholesterol-lowering in *LDLR* (rs6511720, rs1122608, rs688) (LDL-receptor inhibition).

Further details of these SNP effects are given in **Table 1**.

Table 1. Detailed summary of LDL-C lowering genetic variants in *HMGCR*, *NPC1L1*, *CETP*,

PCSK9 and *LDLR* variants from the in Global Lipids Genetics Consortium (GLGC)

Target	SNP	Pathway	EA	OA	EAF	Beta	se	*P*-value
HMGCR	rs12916	LDL-C	T	C	0.57	-0.06061	0.003	7.79E-78
	rs17238484	LDL-C	G	T	0.75	-0.05184	0.005	1.35E-21
	rs5909	LDL-C	G	A	0.90	-0.05102	0.007	4.93E-13
	rs2303152	LDL-C	G	A	0.88	-0.03498	0.005	1.04E-09
	rs10066707	LDL-C	G	A	0.58	-0.0411	0.005	2.97E-19
	rs2006760*	LDL-C	C	G	0.81	-0.04407	0.006	1.67E-13
NPC1L1	rs217386	LDL-C	A	G	0.41	-0.02908	0.003	1.20E-19
	rs2073547	LDL-C	A	G	0.81	-0.03885	0.004	1.92E-21
	rs7791240	LDL-C	T	C	0.91	-0.03404	0.005	1.84E-10
	rs10234070	LDL-C	C	T	0.90	-0.02363	0.005	1.52E-06
	rs2300414	LDL-C	G	A	0.93	-0.02828	0.006	5.45E-06
CETP	rs3764261	LDL-C	A	C	0.29	-0.04471	0.004	2.22E-34
	rs1800775	LDL-C	A	C	0.48	-0.03487	0.003	8.54E-24
	rs1864163	LDL-C	G	A	0.73	-0.03698	0.004	7.97E-21

Gene	SNP	Trait	EA	OA	EAF	Beta	se	p
	rs9929488*	LDL-C	G	C	0.70	-0.03159	0.004	8.15E-13
	rs9989419	LDL-C	G	A	0.60	-0.02344	0.004	2.49E-12
	rs12708967	LDL-C	T	C	0.80	-0.02963	0.004	3.47E-11
	rs289714	LDL-C	A	G	0.79	-0.03032	0.005	2.85E-10
	rs5880*	LDL-C	G	C	0.94	-0.03979	0.008	1.59E-06
PCSK9	rs11206510	LDL-C	C	T	0.15	-0.06871	0.001	2.38E-53
	rs2479409	LDL-C	A	G	0.67	-0.05309	0.001	2.52E-50
	rs2149041*	LDL-C	C	G	0.84	-0.05259	0.001	1.44E-35
	rs2479394	LDL-C	A	G	0.72	-0.03192	0.001	1.58E-19
	rs10888897	LDL-C	T	C	0.40	-0.04192	0.001	8.43E-31
	rs7552841	LDL-C	C	T	0.63	-0.04589	0.001	5.40E-15
	rs562556	LDL-C	G	A	0.19	-0.05292	0.002	6.16E-21
LDLR	rs6511720	LDL-C	T	G	0.11	-0.17482	0.004	3.69E-54
	rs1122608	LDL-C	T	G	0.23	-0.05473	0.003	2.02E-86
	rs688	LDL-C	C	T	0.56	-0.04465	0.003	3.04E-48

EA, effect allele or low-density lipoprotein-cholesterol (LDL-C) lowering allele; OA = other or non-

effect allele; EAF, effect allele frequency; se= standard error. * Palindromic SNPs removed

Beta represents the change in LDL-C levels per copy of the effect allele. For SI conversion of mmol/L

to mg/dL, multiply by 38.7.

There was limited evidence of an effect of genetically-proxied inhibition of HMGCR

and NPC1L1 on combined OC and OPC risk (OR IVW 1.1; 95%CI 0.6, 1.9, p= 0.82 and 1.0; 95%

CI 0.4, 2.7, p= 0.99), respectively. (**Table 2** and **S1 Fig**). A similar result was found for

genetically-proxied LDL-C lowering inhibition of CETP on OC and OPC combined (OR IVW 1.3;

95%CI 0.6, 2.6, p= 0.49) (**Table 2 and S1 Fig**). However, higher risk of combined OC and OPC

was found in relation to genetically-proxied PCSK9 inhibition, equivalent to a 1 mmol/L (38.7

mg/dL) reduction in LDL-C (OR IVW 2.1; 95%CI 1.2, 3.4, p= 0.01; **Table 2 and Fig 1**). This is in

contrast to the reduction in odds seen in relation to cardiovascular disease using the same

instrument (OR IVW 0.6; 95%CI 0.4, 0.8, p <1 x10[-03]; **Fig 2**) in 60,801 cases and 123,504

control subjects enrolled in the CARDIoGRAM consortia studies [38]. There was also some

evidence that LDLR variants, resulting in genetically-proxied reduction in LDL-C equivalent to

a 1 mmol/L (38.7 mg/dL), reduced the risk of combined OC and OPC (OR IVW; 0.7; 95%CI

0.4, 1.0, p= 0.05; **Table 2, Fig 1**).

Fig 1. Forest plot showing the causal effects of *HMGCR*, *NPC1L1, CETP, PCSK9* **and** *LDLR*

variants on the oral and oropharyngeal cancer subsites in GAME-ON. Effect estimates on

oral and oropharyngeal cancer are reported on the log odds scale.

Fig 2. Forest plots showing the causal effects of cholesterol-lowering PCSK9 and LDLR

single nucleotide polymorphisms on coronary heart disease and combined oral/

oropharyngeal cancer in GAME-ON. Effect estimates on oral and oropharyngeal cancer are

reported on the log odds scale.

Table 2. Mendelian randomization results of genetically-proxied inhibition of HMGCR, NPC1L1, CETP, PCSK9 and LDLR with risk of oral and

oropharyngeal cancer including sensitivity analyses in GAME-ON

					IVW		Weighted median		Weighted mode		MR-Egger	
	Outcome	Exposure/ Outcome dataset	Outcome N	Number of SNPs	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P
HMGCR	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	5	1.07 (0.62, 1.84)	0.82	1.20 (0.63, 2.28)	0.58	1.20 (0.57, 2.50)	0.66	1.33 (0.07, 26.58)	0.86
	Oral cancer	GAME-ON/ GLGC	2,990	5	1.49 (0.75, 2.96)	0.25	1.66 (0.73, 3.78)	0.23	1.69 (0.65, 4.42)	0.35	1.25 (0.03, 55.80)	0.91
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	5	0.90 (0.43, 1.85)	0.77	1.01 (0.43, 2.34)	0.99	1.08 (0.44, 2.64)	0.88	0.77 (0.01, 45.07)	0.91
NPC1L1	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	5	1.01 (0.38, 2.69)	0.99	0.90 (0.29, 2.82)	0.86	0.86 (0.24, 3.08)	0.83	0.22 (0.00, 102.42)	0.66
	Oral cancer	GAME-ON/ GLGC	2,990	5	1.02 (0.30, 3.41)	0.98	1.20 (0.29, 5.05)	0.80	1.29 (0.22, 7.41)	0.79	0.09 (0.00, 160.66)	0.57
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	5	0.60 (0.16, 2.25)	0.45	0.60 (0.12, 3.04)	0.53	0.60 (0.10, 3.73)	0.62	0.20 (0.01, 688.64)	0.72
CETP	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	6	1.28 (0.64, 2.55)	0.49	1.24 (0.54, 2.81)	0.61	1.25 (0.43, 3.64)	0.71	0.82 (0.02, 27.60)	0.92
	Oral cancer	GAME-ON/ GLGC	2,990	6	1.65 (0.70, 3.88)	0.25	1.69 (0.61, 4.70)	0.31	1.63 (0.43, 5.87)	0.49	0.42 (0.01, 32.58)	0.72
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	6	1.12 (0.45, 2.77)	0.81	1.05 (0.35, 3.20)	0.93	0.73 (0.17, 3.07)	0.69	1.50 (0.02, 142.22)	0.87

					IVW							
PCSK9	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	6	2.05 (1.24, 3.38)	0.01	2.21 (1.12, 4.08)	0.01	2.19 (0.81, 5.92)	0.18	1.83 (0.17, 20.00)	0.65
	Oral cancer	GAME-ON/ GLGC	2,990	6	1.62 (0.89, 2.94)	0.11	1.80 (0.90, 3.62)	0.10	2.00 (0.73, 5.48)	0.23	2.17 (0.15, 32.13)	0.60
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	6	3.49 (1.58, 7.68)	2.00 E-03	3.19 (1.40, 7.26)	0.01	2.73 (0.86, 8.70)	0.15	1.99 (0.04, 92.11)	0.74
LDLR	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	3	0.65 (0.42, 1.00)	0.05	0.71 (0.47, 1.08)	0.11	0.74 (0.47, 1.15)	0.31	0.90 (0.41, 1.95)	0.83
	Oral cancer	GAME-ON/ GLGC	2,990	3	0.53 (0.32, 0.87)	0.01	0.56 (0.32, 0.98)	0.04	0.57 (0.32, 1.04)	0.21	0.56 (0.18, 1.76)	0.50
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	3	0.90 (0.53, 1.52)	0.69	0.91 (0.55, 1.53)	0.73	1.08 (0.62, 1.89)	0.81	1.56 (0.64, 3.82)	0.51

Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals; P, p-value.

OR represents the exponential change in odds of oral/ oropharyngeal squamous cell carcinoma per genetically-proxied inhibition of drug target equivalent

to a 1 mmol/L decrease in LDL-C.

Stratification by cancer subsite in GAME-ON. When stratified by subsite, the

adverse effect of PCSK9 appeared to be mainly in the oropharynx, (OR IVW 3.5; 95%CI 1.6,

7.7, p= 2 x10^{-03}), with limited evidence in the oral cavity (OR IVW 1.6; 0.9, 2.94, p= 0.11)

(**Table 2 & Fig 1**). The effects appeared stronger in OPC versus OC, but with overlapping

confidence intervals. LDLR was associated with a reduction in risk of OC (OR IVW 0.5; 95%CI

0.3, 0.9, p= 0.01), but there was little evidence of an association with OPC (OR IVW 0.9;

95%CI 0.5, 1.5, p= 0.69) (**Table 2 and Fig 1**). For both PCSK9 and LDLR associations, the

direction of effect was generally consistent across the four MR methods tested (**Table 2**).

Secondary analysis in GAME-ON. SNPs were also used to proxy circulating levels of LDL-C

(77 SNPs), high-density lipoprotein cholesterol (HDL-C) (85 SNPs), total triglyceride (54

SNPs), total cholesterol (82 SNPs), apolipoprotein A (9 SNPs) and apolipoprotein B (14 SNPs)

(**S1 Table**). There was limited evidence of an effect of any of these other lipid traits on either

OC or OPC (**Table 3 and S2 Fig**).

437 **Table 3.** Mendelian randomization results of circulating lipid traits with risk of oral and

438 oropharyngeal cancer in GAME-ON

Target	N SNPs	Outcome	IVW OR (95% CI)	*P*-value
LDL-C	77	Oral/ Oropharyngeal cancer	0.98 (0.87, 1.11)	0.79
		Oral cancer	0.99 (0.85, 1.15)	0.88
		Oropharyngeal cancer	1.03 (0.87, 1.21)	0.76
HDL-C	85	Oral/ Oropharyngeal cancer	0.98 (0.83, 1.16)	0.79
		Oral cancer	1.08 (0.88, 1.32)	0.45
		Oropharyngeal cancer	0.87 (0.71, 1.05)	0.15
Total triglycerides	54	Oral/ Oropharyngeal cancer	1.19 (1.01, 1.04)	0.04
		Oral cancer	1.19 (0.96, 1.46)	0.11
		Oropharyngeal cancer	1.19 (0.96, 1.47)	0.12
Total cholesterol	82	Oral/ Oropharyngeal cancer	1.04 (0.91, 1.18)	0.55
		Oral cancer	1.09 (0.93, 1.28)	0.30
		Oropharyngeal cancer	1.00 (0.84, 1.20)	0.96
Apolipoprotein A	9	Oral/ Oropharyngeal cancer	0.87 (0.73, 1.03)	0.11
		Oral cancer	0.90 (0.73, 1.12)	0.34
		Oropharyngeal cancer	0.82 (0.65, 1.04)	0.10
Apolipoprotein B	14	Oral/ Oropharyngeal cancer	1.04 (0.88, 1.22)	0.67
		Oral cancer	1.15 (0.89, 1.49)	0.29
		Oropharyngeal cancer	1.00 (0.83, 1.21)	0.98

Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals.

IVW OR represents the exponential change in odds of oral/ oropharyngeal squamous cell carcinoma
per SD increase in the circulating lipid trait (one SD for LDL-C = 38.7 mg/dL, HDL-C = 15.5 mg/dL,
Apolipoprotein A = 0.32 g/L, Apolipoprotein B = 0.52 g/L, Total triglycerides = 90.7 mg/dL, Total
cholesterol = 41.8 mg/dL).

Sensitivity analyses. IVW, MR Egger, weighted median, simple and weighted mode were

carried out, in addition to IVW analysis accounting for LD structure (**S2.1-2.5 Tables**). The

results adjusting for SNP correlation followed the same pattern as the main results (**S3**

Table). There was limited evidence of weak instrument bias being present (F-statistic >10)

and the proportion of variance in the phenotype (R^2) explained by the genetic instruments

ranged from 0.1 to 6% (**S4 Table**). In both primary and secondary analyses there was limited

evidence of heterogeneity in the SNP effect estimates for IVW and MR Egger regression,

except for in HDL-C (Q IVW 115.7, p= 0.01; Q MR Egger 115.6, p= 0.01) (**S5 and S6 Tables**).

MR Egger intercepts also indicated limited evidence of directional pleiotropy (**S7 and**

S8 Tables). For the primary analysis there were no clear outliers in both scatter and leave-

one-out plots (**Fig 3 and S3-6   Figs**) and MR-PRESSO detected no individual outliers (**S9**

Table). Where there was evidence of violation of the NOME assumption for the HMGCR,

NPC1L1 and CETP instruments (i.e. I^2 statistic <0.90) (**S10 Table**), MR-Egger was performed

with SIMEX correction and effects were still consistent with the null (**S11 Table**).

Fig 3. Scatter plots for LDLR and PCSK9 single nucleotide polymorphisms effect on

combined oral/ oropharyngeal cancer in GAME-ON.

Replication in UK Biobank and meta-analysis of results. Primary MR analyses as described

above were replicated in UK Biobank, showing limited evidence of an effect of genetically-

proxied inhibition of HMGCR, NPC1L1, CETP, PCSK9 and LDLR on risk of OC and OPC (**S12**

Table). Following IVW fixed-effects meta-analysis of GAME-ON and UK Biobank MR results,

there was a consistently strong effect of genetically-proxied PSCK9 inhibition on combined

OC and OPC (OR IVW 1.8; 95%CI 1.2, 2.8), with good concordance between studies (I^2= 22%)

and methods used (**Fig 4** and **S7 Fig**). Effects for PCSK9 appeared stronger in relation to OPC

(OR IVW 2.6; 95%CI 1.4, 4.9) than OC (OR IVW 1.4; 95%CI 0.8, 2.4), but with moderate

heterogeneity between studies (I^2= 41%) (**Fig 4**). Conversely, the protective effect for LDLR

on OC and OPC combined was also consistent in the meta-analysis (OR IVW 0.7; 95%CI 0.5,

1.0), with good concordance between studies (I^2= 0%) (**Fig 5** and **S7 Fig**). However, the

protective effect seen specifically in relation to OC in GAME-ON (OR IVW 0.5; 95%CI 0.3, 0.9)

was not replicated in UK Biobank (OR IVW 1.6; 95%CI 0.5, 4.8), with strong evidence of

heterogeneity between the studies (I^2= 66%).

Fig 4. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-

lowering *PCSK9* single nucleotide polymorphisms on head and neck cancer subsites.

Fig 5. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-

lowering *LDLR* single nucleotide polymorphisms on head and neck cancer subsites.

Discussion

We found limited evidence for a role of cholesterol-lowering in OC and OPC risk. This

included the absence of a protective effect of genetically-proxied inhibition of HMGCR,

suggesting previous observational studies investigating the relationship between statins and

head and neck cancer risk may be subject to residual confounding or bias. However, we did

observe an adverse effect of PCSK9 inhibition on OC and OPC risk, which was of a similar

magnitude to the protective effect seen in relation to cardiovascular disease using the same

genetic instrument (**Fig 2**). This PCSK9 effect was evident in both the GAME-ON (n= 6,034 OC

and OPC cases and n= 6,585 controls) and UK Biobank datasets (n= 839 OC and OPC cases

and n= 372,016 controls). We also found some evidence for a protective effect of

cholesterol-lowering variants in *LDLR* on OC and OPC risk in both studies. The IVW analysis

for HMGCR, NPC1L1, CETP, PCSK9 and LDLR accounting for LD structure (r^2<0.2) followed

the same pattern as the main results (**S3 Table**).

Association between PCSK9, LDLR and cancer risk. Despite the lack of consistent evidence

for a role of cholesterol-lowering on risk of OC or OPC in this study, individual effects of both

PCSK9 and LDLR were demonstrated which may implicate a role for these drug targets in the

development of OC or OPC via other mechanisms. The effects identified in the present study

are directionally consistent with a recent MR analysis of 1,615 combined head and neck

cancer cases from UK Biobank, which also found that a 1 SD unit increase in LDL-C proxied

by PCSK9 and LDLR was associated with a reduction (OR 0.7 95%CI 0.4, 1.4, p= 0.35) and

increase in odds (OR 1.6 95%CI 1.0, 2.4, p= 0.05) of head and neck cancer, respectively [29].

The opposing effects of PCSK9 and LDLR in this study also suggests that cholesterol lowering

is unlikely to be the main mechanism of action. However, this previous analysis is limited by

the relatively small number of cases and heterogeneity of head and neck cancer subtypes,

with no selection for the histological subtype of squamous cell carcinoma. In the present

study, we focused specifically on oral and oropharyngeal subtypes of HNSCC.

Beyond the established role of *PCSK9* in cholesterol homeostasis, other potential

pleiotropic effects are not well understood. Variants in *PCSK9* have been associated with an

increased risk of diabetes (OR 1.1, 95%CI 1.0, 1.2 for each 10 mg per decilitre decrease in

LDL-C) [28]. However, a recent phenome-wide association study (PheWAS) did not

find *PCSK9* or *LDLR* to be correlated with any non-lipid-related phenotypes, including

diabetes [49]. There is limited *in vivo* and *in vitro* evidence that *PCSK9* might be involved in

both cell proliferation and apoptosis. The gene was initially designated as NARC1 (neural

apoptosis-regulated convertase 1), involved in apoptosis of cerebellar neurons [50] and

PCSK9 has since been found to be upregulated in some cancers [51, 52].

One suggested mechanism for a link with cancer progression is that the increased

expression of *PCSK9* prevents LDL-receptor (LDLR) recycling, leading to

hypercholesterolaemia and more exogenous lipid to support the proliferation of the tumour

[50]. Our study suggests the opposite, that genetically-proxied inhibition of *PCSK9* results in

an increased risk of OC or OPC. We hypothesise that access to intracellular LDL-C could in

fact be pro-tumourigenic, providing a favourable environment for a developing tumour cell,

maintaining membrane integrity and promoting cell division. Therapies such as statins,

ezetimibe, and PCSK9 inhibitors may all lower LDL-C level through the upregulation of LDL-

receptors, resulting in elevated intracellular cholesterol. However, cancer mechanisms are

often context dependent and perhaps only the expression of *PCSK9* and *LDLR* is relevant in

head and neck cancer. CETP inhibitors instead block the transfer of cholesteryl ester from

HDL-C to LDL-C, thereby raising HDL-C and lowering LDL-C (and apolipoprotein B), as well as

enhancing reverse cholesterol transport [53]. Unlike statins, CETP inhibitors do not appear

to increase the risk of type 2 diabetes, thought to be as a result of pancreatic islet cell

cholesterol accumulation with use of other cholesterol-lowering drugs [54]. Therefore, the

absence of effect when proxying *CETP* inhibition in this study, supports the possible

mechanism of LDL-C uptake via the LDL-receptor in OC or OPC.

While both *PCSK9* [55] and *LDLR* [56] are expressed in head and neck tumours, this was not

evident in normal oral or oropharyngeal tissue, and sufficient tissue is currently not

available in expression datasets [57]. Recent studies have associated elevated *PCSK9* with

alcohol use disorder, including the interesting possibility of using anti-PSCK9 monoclonal

antibodies for the treatment of alcoholic liver disease [58, 59]. Given that alcohol is a well-

known risk factor for HNSCC, this pleiotropy could have partially explained the effect seen in

our study, however we proxied the inhibition of *PCSK9* and so would have expected to see a

protective effect of this gene in HNSCC cases who may have been heavy alcohol drinkers.

Further investigation is required to untangle the relationship between *PCSK9*, alcohol and

head and neck cancer.

Comparison with previous studies. It is believed that statins could play a potential role in

cancer chemoprevention which may reduce the risk of some site-specific cancers such as

prostate [60] and ovarian [30], but not all. Some of these studies have reported cancer risk

reductions by as much as 50 – 65% [61-63]. However, meta-analyses and clinical trials have

contradicted these findings [64, 65]. In addition to confounding, immortal time bias likely

inflated observational results because, to be classified as a long-term statin user

necessitates that users survived without cancer over a long period [19, 66]. Dickerman et al.

used electronic records from 733,804 adults with 10-year follow-up to emulate a trial

design. To achieve this a pre-specified protocol was set, including eligibility criteria and

checks were made to ensure effect estimates for statins on cancer were comparable

between the large observational dataset and trial. The authors found little indication that

statin therapy influences cancer incidence, which was consistent with the analyses of

randomised trials (with a 10-year cancer-free survival difference of −0.3% 95%CI −1.5%,

0.5%) [19]. Nonetheless, recent MR studies [29, 30] have identified an association between

variants in *HMGCR* with cancer risk, but not alternative cholesterol-lowering treatments or

genetically-predicted LDL-C, suggesting that statins may reduce cancer risk through a

cholesterol independent pathway. A recent case-control study of over 11,000 participants

found an inverse association between statin use and the occurrence of HNSCC (OR 0.86,

95%CI 0.77, 0.95, p= <0.01, of prior statin exposure for cases compared to propensity

score-matched controls) [18]. However, a wider systematic review found that the evidence

for the role of statins in the prevention of HNSCC was limited [67]. As HNSCC incidence is a

rare outcome, randomised controls trials are not feasible, so we must be cautious

interpreting the available observational findings given the potential for bias and

confounding as discussed previously.

In contrast to previous MR studies assessing overall cancer risk [29] and ovarian

specific risk [30], the MR carried out here in relation to OC and OPC showed no effect using

genetic instruments for HMGCR (statins). There was also limited evidence for a causal effect

of NPC1L1 (ezetimibe), CETP (CETP inhibitors) as well as a number of other circulating lipid

traits on OC or OPC. Therefore, it remains unclear as to whether the effects observed with

PCSK9 and LDLR are via LDL-C lowering or another less well-established pathway [68, 69],

such as receptor regulation for viral entry, synthesis of sex hormones and resultant

dysregulated metabolism [70-72].

Strengths and limitations of this study. Protective associations between cholesterol-

lowering therapies such as statins and head and neck cancer risk seen in previous

observational studies could be a result of reverse causation, immortal time bias, lack of

randomisation or confounding by socioeconomic status, smoking or HPV infection, for

example. Our study applied MR in an attempt to overcome these issues, using the largest

number of SNPs identified from the latest GWAS for both cholesterol-lowering and head

and neck cancer that could be identified in the literature [25, 34]. A series of pleiotropy-

robust MR methods and outlier detection were applied to rigorously explore the possibility

that findings were not biased as a result of pleiotropy. However, there was no HPV data

available in these summary results to enable more detailed stratified analysis of OPC. We

did replicate findings for PCSK9 and LDLR, but the number of cases are low. Finally, most

participants in the GAME-ON network [34] were of European or North American decent,

with only around 11% from South America, and participants included in the UK Biobank

analysis were exclusively of European descent, so more work is required to determine if our

results translate to other ancestry groups.

In conclusion, our MR analyses provided little evidence for a role of cholesterol

lowering in OC or OPC risk although effects of genetically-proxied inhibition of *PCSK9* and

cholesterol-lowering variants in *LDLR* were observed in relation to OPC and OC risk. Given

the lack of a common pathway to carcinogenesis in OC or OPC, metabolic targets that may

be common to all tumours, regardless of the activated molecular pathway, could help

simplify a preventative or therapeutic approach [73]. Replication of our findings in other

head and neck cancer datasets and use of individual-level follow-up data with HPV status

could provide further insight into the effect of these genetic instruments on risk, treatment

outcomes and survival in head and neck cancer. With more evidence, future randomised

control trials could focus on treating high risk OC or OPC groups, such as those with severe

dysplasia or who are HPV-16 E6 positive, with cholesterol-lowering therapies.

Data availability statement

Code availability statement

Two-sample MR analyses were conducted using the "TwoSampleMR" package in R

(version 3.5.3). A copy of the code used in this analysis will be made available at:

https://github.com/rcrichmond/cholesterol_lowering_headandneckcancer

Acknowledgements

M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and

is currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship.

This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z].

For the purpose of open access, the author has applied a CC BY public copyright licence to

any Author Accepted Manuscript version arising from this submission. R.C.R. is a de Pass VC

research fellow at the University of Bristol. J.T. is supported by an Academy of Medical

Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust,

Global Challenges Research Fund (GCRF), the Government Department of Business, Energy

and Industrial strategy, the British Heart Foundation and Diabetes UK (SBF004\1079).

R.M.M. was supported by a Cancer Research UK (C18281/A19169) programme grant (the

Integrative Cancer Epidemiology Programme) and is part of the Medical Research Council

Integrative Epidemiology Unit at the University of Bristol supported by the Medical Research

Council (MC_UU_12013/1, MC_UU_12013/2, and MC_UU_12013/3) and the University of

Bristol. JY is supported by a Cancer Research UK Population Research Postdoctoral

Fellowship (C68933/A28534). R.M.M. and A.R.N. are supported by the National Institute for

Health Research (NIHR) Bristol Biomedical Research Centre which is funded by the National

Institute for Health Research (NIHR) and is a partnership between University Hospitals

Bristol and Weston NHS Foundation Trust and the University of Bristol. This publication

presents data from the Head and Neck 5000 study. The study was a component of

independent research funded by the NIHR under its Programme Grants for Applied

Research scheme (RP-PG-0707-10034). The views expressed in this publication are those of

the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Core funding was also provided through awards from Above and Beyond, University

Hospitals Bristol Research Capability Funding and the NIHR Senior Investigator award to

A.R.N. Human papillomavirus (HPV) serology was supported by a Cancer Research UK

Programme Grant, the Integrative Cancer Epidemiology Programme (grant number:

C18281/A19169). B.D. and the University of Pittsburgh head and neck cancer case-control

study are supported by US National Institutes of Health (NIH) grants: P50 CA097190, P30

CA047904 and R01 DE025712. The genotyping of the HNSCC cases and controls was

performed at the Center for Inherited Disease Research (CIDR) and funded by the US

National Institute of Dental and Craniofacial Research (NIDCR; 1X01HG007780-0). The

University of North Caroline (UNC) CHANCE study was supported in part by the National

Cancer Institute (R01-CA90731). E.E.V and D.L are supported by Diabetes UK (17/0005587).

E.E.V is also supported by the World Cancer Research Fund (WCRF UK), as part of the World

Cancer Research Fund International grant programme (IIG_2019_2009). E.H.T and P.S. were

supported by the GENCAPO/FAPESP grant (10/51168-0).

Competing Interests

The authors declare no conflicts of interest. The funders had no role in the design of

the study; the collection, analysis, and interpretation of the data; the writing of the

manuscript; and the decision to submit the manuscript for publication. The authors alone

are responsible for the views expressed in this article.

References

685
1.   Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral

Oncol. 2009;45(4-5):309-16.

2.   Saba NF, Goodman M, Ward K, Flowers C, Ramalingam S, Owonikoko T, et al. Gender

and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral

tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-

based analysis. Oncology. 2011;81(1):12-20.

3.   (CRUK) CRU. Head and neck cancer statistics 2019 [cited 2019 11/04/2019]. Available

from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-

cancer-type/head-and-neck-cancers#heading-Two.

4.   Mehanna H, Kong A, Ahmed SK. Recurrent head and neck cancer: United Kingdom

National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(S2):S181-S90.

5.   De Boer MF, McCormick LK, Pruyn JF, Ryckman RM, van den Borne BW. Physical and

psychosocial correlates of head and neck cancer: a review of the literature. Otolaryngol

Head Neck Surg. 1999;120(3):427-36.

6.   Thomas SJ, Penfold CM, Waylen A, Ness AR. The changing aetiology of head and neck

squamous cell cancer: A tale of three cancers? Clin Otolaryngol. 2018;43(4):999-1003.

7.   Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human

papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med.

2010;363(1):24-35.

8.   Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M. HPV in oropharyngeal

cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital. 2014;34(5):299-

309.

9.   Sleire L, Forde HE, Netland IA, Leiss L, Skeie BS, Enger PO. Drug repurposing in

cancer. Pharmacol Res. 2017;124:74-91.

10.   Hu M, Cheung BM, Tomlinson B. Safety of statins: an update. Ther Adv Drug Saf.

2012;3(3):133-44.

11.   Audi S, Burrage DR, Lonsdale DO, Pontefract S, Coleman JJ, Hitchings AW, et al. The

'top 100' drugs and classes in England: an updated 'starter formulary' for trainee

prescribers. British Journal of Clinical Pharmacology. 2018;84(11):2562-71.

12.   Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA

reductase. Science. 2001;292(5519):1160-4.

13.   Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, et al.

Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein

Levels and Cardiovascular Risk. JAMA. 2017;318(10):947-56.

14.   Nielsen SF, Nordestgaard BG, Bojesen SE. Statin Use and Reduced Cancer-Related

Mortality. New Engl J Med. 2012;367(19):1792-802.

15.   Mehibel M, Ortiz-Martinez F, Voelxen N, Boyers A, Chadwick A, Telfer BA, et al.

Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting

monocarboxylate transporters. Sci Rep. 2018;8(1):16804.

16.   Chawda JG, Jain SS, Patel HR, Chaduvula N, Patel K. The relationship between serum

lipid levels and the risk of oral cancer. Indian J Med Paediatr Oncol. 2011;32(1):34-7.

17.   Mehta R, Gurudath S, Dayansoor S, Pai A, Ganapathy KS. Serum lipid profile in

patients with oral cancer and oral precancerous conditions. Dent Res J (Isfahan).

2014;11(3):345-50.

18.   Kao LT, Hung SH, Kao PF, Liu JC, Lin HC. Inverse association between statin use and

head and neck cancer: Population-based case-control study in Han population. Head Neck-J

Sci Spec. 2019;41(5):1193-8.

19.   Dickerman BA, Garcia-Albeniz X, Logan RW, Denaxas S, Hernan MA. Avoidable flaws

in observational analyses: an application to statins and cancer. Nat Med. 2019;25(10):1601-

6.

20.   Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology

contribute to understanding environmental determinants of disease? Int J Epidemiol.

2003;32(1):1-22.

21.   Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal

inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89-98.

22.   Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a

guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.

23.   Walker VM, Smith GD, Davies NM, Martin RM. Mendelian randomization: a novel

approach for the prediction of adverse drug events and drug repurposing opportunities. Int J

Epidemiol. 2017;46(6):2078-89.

24.   Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al.

Biological, clinical and population relevance of 95 loci for blood lipids. Nature.

2010;466(7307):707-13.

25.   Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al.

Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274-+.

26.   Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-

density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic,

epidemiologic, and clinical studies. A consensus statement from the European

Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72.

27.   Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random

allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease

mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian

randomization study. J Am Coll Cardiol. 2015;65(15):1552-61.

28.   Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al.

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J

Med. 2016;375(22):2144-53.

29.   Carter P, Vithayathil M, Kar S, Potluri R, Mason AM, Larsson SC, et al. Predicting the

effect of statins on cancer risk using genetic variants: a Mendelian randomization study in

UK Biobank. medRxiv. 2020:2020.02.28.20028902.

30.   Yarmolinsky J, Bull CJ, Vincent EE, Robinson J, Walther A, Smith GD, et al. Association

Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian

Cancer. JAMA. 2020;323(7):646-55.

31.   Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-

specific haplotype structure and linking correlated alleles of possible functional variants.

Bioinformatics. 2015;31(21):3555-7.

32.   Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian

Randomization Study of ACLY and Cardiovascular Disease. N Engl J Med. 2019;380(11):1033-

42.

33.   Kettunen J, Demirkan A, Wurtz P, Draisma HH, Haller T, Rawal R, et al. Genome-wide

study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA.

Nat Commun. 2016;7:11122.

34.   Lesseur C, Diergaarde B, Olshan AF, Wunsch V, Ness AR, Liu G, et al. Genome-wide

association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer.

Nat Genet. 2016;48(12):1544-50.

35.   Consortium O. Consortium launches genotyping effort. Cancer Discov.

2013;3(12):1321-2.

36.   Dudding T, Johansson M, Thomas SJ, Brennan P, Martin RM, Timpson NJ. Assessing

the causal association between 25-hydroxyvitamin D and the risk of oral and oropharyngeal

cancer using Mendelian randomization. Int J Cancer. 2018;143(5):1029-36.

37.   Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian

randomization studies. Int J Epidemiol. 2013;42(5):1497-501.

38.   Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive

1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.

Nat Genet. 2015;47(10):1121-30.

39.   Hemani G, Bowden J, Smith GD. Evaluating the potential role of pleiotropy in

Mendelian randomization studies. Hum Mol Genet. 2018;27(R2):R195-R208.

40.   Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid

instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol.

2015;44(2):512-25.

41.   Bowden J, Smith GD, Haycock PC, Burgess S. Consistent Estimation in Mendelian

Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet

Epidemiol. 2016;40(4):304-14.

42.   Hartwig FP, Smith GD, Bowden J. Robust inference in summary data Mendelian

randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46(6):1985-

98.

43.   Bowden J, Del Greco MF, Minelli C, Smith GD, Sheehan NA, Thompson JR. Assessing

the suitability of summary data for two-sample Mendelian randomization analyses using

MR-Egger regression: the role of the I-2 statistic. Int J Epidemiol. 2016;45(6):1961-74.

44.   Bowden J, Spiller W, Del Greco F, Sheehan N, Thompson J, Minelli C, et al. Improving

the visualization, interpretation and analysis of two-sample summary data Mendelian

randomization via the Radial plot and Radial regression. Int J Epidemiol. 2018;47(4):1264-78.

45.   Verbanck M, Chen CY, Neale B, Do R. Publisher Correction: Detection of widespread

horizontal pleiotropy in causal relationships inferred from Mendelian randomization

between complex traits and diseases. Nat Genet. 2018;50(8):1196.

46.   Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. Genome-wide

genetic data on ~500,000 UK Biobank participants. bioRxiv. 2017:166298.

47.   Schwarzer G. meta: an R package for metaanalysis. R News. 2007;7:40-5.

48.   Higgins SG. Measuring inconsistency in metaanalyses. BMJ Br Med J. 2003;327:557-

60.

49.   Safarova MS, Satterfield BA, Fan X, Austin EE, Ye Z, Bastarache L, et al. A phenome-

wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR. NPJ Genom

Med. 2019;4:3.

50.   Stoekenbroek RM, Lambert G, Cariou B, Hovingh GK. Inhibiting PCSK9 - biology

beyond LDL control. Nat Rev Endocrinol. 2018;15(1):52-62.

51.   Lee S, Zhang C, Liu Z, Klevstig M, Mukhopadhyay B, Bergentall M, et al. Network

analyses identify liver-specific targets for treating liver diseases. Mol Syst Biol.

2017;13(8):938.

52.   Marimuthu A, Subbannayya Y, Sahasrabuddhe NA, Balakrishnan L, Syed N, Sekhar

NR, et al. SILAC-based quantitative proteomic analysis of gastric cancer secretome.

Proteomics Clin Appl. 2013;7(5-6):355-66.

53.   Dong B, Singh AB, Fung C, Kan K, Liu J. CETP inhibitors downregulate hepatic LDL

receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent

mechanism. Atherosclerosis. 2014;235(2):449-62.

54.   Barter PJ, Cochran BJ, Rye KA. CETP inhibition, statins and diabetes. Atherosclerosis.

2018;278:143-6.

55.   Atlas THP. PCKS9 2020 [Available from:

https://www.proteinatlas.org/ENSG00000169174-PCSK9/pathology.

56.   Atlas THP. LDLR 2020 [Available from:

https://www.proteinatlas.org/ENSG00000130164-LDLR/pathology.

57.   Atlas TH. LDLR Tissue 2020 [Available from:

https://www.proteinatlas.org/ENSG00000130164-LDLR/tissue.

58.   Lee JS, Mukhopadhyay P, Matyas C, Trojnar E, Paloczi J, Yang YR, et al. PCSK9

inhibition as a novel therapeutic target for alcoholic liver disease. Scientific Reports.

2019;9(1):17167.

59.   Lee JS, Rosoff D, Luo A, Longley M, Phillips M, Charlet K, et al. PCSK9 is Increased in

Cerebrospinal Fluid of Individuals With Alcohol Use Disorder. Alcoholism: Clinical and

Experimental Research. 2019;43(6):1163-9.

60.   Wang K, Gerke TA, Chen X, Prosperi M. Association of statin use with risk of Gleason

score-specific prostate cancer: A hospital-based cohort study. Cancer Medicine.

2019;8(17):7399-407.

61.   Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and

the risk of colorectal cancer. N Engl J Med. 2005;352(21):2184-92.

62.   Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer

in humans: a large case-control study of US veterans. Chest. 2007;131(5):1282-8.

63.   Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, et al. Statins

and prostate cancer risk: a case-control study. Am J Epidemiol. 2005;162(4):318-25.

64.   Cholesterol Treatment Trialists C, Emberson JR, Kearney PM, Blackwell L, Newman C,

Reith C, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of

individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One.

2012;7(1):e29849.

65.   Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a

meta-analysis. JAMA. 2006;295(1):74-80.

66.   Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial

prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin

Epidemiol. 2016;79:70-5.

67. Saka Herran C, Jane-Salas E, Estrugo Devesa A, Lopez-Lopez J. Protective effects of

metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic

review. Oral Oncol. 2018;85:68-81.

68. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, et al. Microarray

and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas.

Neoplasia. 2002;4(4):337-46.

69. Osmak M. Statins and cancer: current and future prospects. Cancer Lett.

2012;324(1):1-12.

70. Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and

Cancer-Related Mortality. Physiol Rev. 2015;95(3):727-48.

71. Joost HG. Diabetes and cancer: Epidemiology and potential mechanisms. Diabetes

Vasc Dis Re. 2014;11(6):390-4.

72. Hursting SD, DiGiovanni J, Dannenberg AJ, Azrad M, LeRoith D, Demark-Wahnefried

W, et al. Obesity, Energy Balance, and Cancer: New Opportunities for Prevention. Cancer

Prev Res. 2012;5(11):1260-72.

73. Bhat M, Skill N, Marcus V, Deschenes M, Tan X, Bouteaud J, et al. Decreased PCSK9

expression in human hepatocellular carcinoma. BMC Gastroenterol. 2015;15:176.

Fig 1. Forest plot showing the causal effects of *HMGCR*, *NPC1L1, CETP, PCSK9* and *LDLR*

variants on the oral and oropharyngeal cancer subsites in GAME-ON.

Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.

Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.

Fig 2. Forest plots showing the causal effects of cholesterol-lowering *PCSK9* and *LDLR* single nucleotide polymorphisms on coronary heart disease and combined oral/ oropharyngeal cancer in GAME-ON.

Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.

Fig 3. Scatter plots for *LDLR* and PCSK9 single nucleotide polymorphisms effect on combined oral/ oropharyngeal cancer in GAME-ON.

Fig 4. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-lowering *PCSK9* single nucleotide polymorphisms on head and neck cancer subsites .

Fig 5. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-lowering

LDLR single nucleotide polymorphisms on head and neck cancer subsites